# Yoann Bonnamour

> Yoann Bonnamour is a Series A investor at Mérieux Equity Partners backing Medical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Mérieux Equity Partners](https://shizune.co/investors/profile/m%C3%A9rieux-equity-partners)
- Total investments: 4
- Last investment: Sep 2024
- Lead investor: 75%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/yoann-bonnamour-735b2430

Yoann Bonnamour is a Series A investor at Mérieux Equity Partners focused on Medical and Medical Device. Yoann Bonnamour - Investment Manager @ Mérieux Equity Partners

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 50% |
| Medical Device | 2 | 50% |
| Hospital | 1 | 25% |
| Wellness | 1 | 25% |
| Health Care | 1 | 25% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 75% |
| Series B | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 2 | 50% |
| France | 1 | 25% |
| Switzerland | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CorFlow Therapeutics | CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients. | $48.5M | Series B | Sep 10, 2024 |  |
| Prothea Technologies | Prothea Technologies is a private medical technology business to provide lung cancer biopsy and therapy in a single hospital visit. | $13M | Series A | Apr 09, 2024 |  |
| Broken String Biosciences | Broken String Biosciences is developing a platform of novel sequencing tools to assess genome stability and to unlock the next generation of innovative medicines, including cell and gene therapies. | $15M | Series A | Sep 18, 2023 |  |
| Cairdac | Cairdac is a manufacturer of autonomous leadless pacing transcatheter system capable of powering the device with no battery-life limitation. | $18.8M | Series A | Mar 31, 2022 |  |

4 of 4 investments shown.

## Co-investors
- [Mérieux Equity Partners](https://shizune.co/investors/profile/merieux-equity-partners) — VC Fund, 4 deals together
- [415 Capital](https://shizune.co/investors/profile/415-capital-management) — VC Fund, 1 deal together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 1 deal together
- [Broadview Ventures](https://shizune.co/investors/profile/broadview-ventures) — VC Fund, 1 deal together
- [Carvest Crédit Agricole Régions Investissement](https://shizune.co/investors/profile/crdit-agricole-rgions-investissement) — VC Fund, 1 deal together
- [DvH Ventures](https://shizune.co/investors/profile/dvh-ventures) — VC Fund, 1 deal together

## About Mérieux Equity Partners

VC Fund · Lyon, France

Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP currently managesmore than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.

4 contacts available at Mérieux Equity Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Yoann Bonnamour | Investment Manager | https://shizune.co/investors/profile/yoann-bonnamour |
| Jean-Francois Billet | Senior Partner | https://shizune.co/investors/profile/jean-francois-billet |
| Jean-Guillaume Lafay | Operating Partner | https://shizune.co/investors/profile/jean-guillaume-lafay |
| Thierry Chignon | Senior Partner | https://shizune.co/investors/profile/thierry-chignon-2 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Yoann Bonnamour invest in?

Yoann Bonnamour invests primarily in Medical, Medical Device and Hospital startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Yoann Bonnamour last invest?

The most recent investment recorded for Yoann Bonnamour closed in Sep 2024. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co